Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Denosumab Osteoporosis Submission To Await Three-Year Data

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm had previously planned to submit denosumab for postmenopausal osteoporosis with two-year data.

You may also be interested in...



Amgen’s Four-Year Denosumab Data Shows Bone Density Benefit

Wyeth also presents the first Phase III fracture data on its potential competitor Viviant.

Amgen’s Four-Year Denosumab Data Shows Bone Density Benefit

Wyeth also presents the first Phase III fracture data on its potential competitor Viviant.

Amgen Partners With Daiichi-Sankyo For Denosumab In Japan

Amgen and Daiichi-Sankyo have entered a collaboration and license agreement for development and commercialization of Amgen's investigational bone loss therapy denosumab in Japan, the companies announced July 11

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel